Neurosense Therapeutics Stock Market Value
| NRSN Stock | USD 0.85 0.15 15.00% |
| Symbol | Neurosense |
Will Biotechnology sector continue expanding? Could Neurosense diversify its offerings? Factors like these will boost the valuation of Neurosense Therapeutics. Anticipated expansion of Neurosense directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neurosense Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Neurosense Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Neurosense Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Neurosense Therapeutics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Neurosense Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurosense Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Neurosense Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Neurosense Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neurosense Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neurosense Therapeutics.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in Neurosense Therapeutics on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding Neurosense Therapeutics or generate 0.0% return on investment in Neurosense Therapeutics over 90 days. NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments f... More
Neurosense Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neurosense Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neurosense Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.33 | |||
| Information Ratio | (0.0007) | |||
| Maximum Drawdown | 34.62 | |||
| Value At Risk | (7.48) | |||
| Potential Upside | 12.82 |
Neurosense Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurosense Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neurosense Therapeutics' standard deviation. In reality, there are many statistical measures that can use Neurosense Therapeutics historical prices to predict the future Neurosense Therapeutics' volatility.| Risk Adjusted Performance | 0.014 | |||
| Jensen Alpha | 0.0209 | |||
| Total Risk Alpha | (0.26) | |||
| Sortino Ratio | (0.0008) | |||
| Treynor Ratio | 0.1032 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neurosense Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neurosense Therapeutics February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.014 | |||
| Market Risk Adjusted Performance | 0.1132 | |||
| Mean Deviation | 4.63 | |||
| Semi Deviation | 5.06 | |||
| Downside Deviation | 5.33 | |||
| Coefficient Of Variation | 14956.67 | |||
| Standard Deviation | 6.34 | |||
| Variance | 40.14 | |||
| Information Ratio | (0.0007) | |||
| Jensen Alpha | 0.0209 | |||
| Total Risk Alpha | (0.26) | |||
| Sortino Ratio | (0.0008) | |||
| Treynor Ratio | 0.1032 | |||
| Maximum Drawdown | 34.62 | |||
| Value At Risk | (7.48) | |||
| Potential Upside | 12.82 | |||
| Downside Variance | 28.45 | |||
| Semi Variance | 25.63 | |||
| Expected Short fall | (6.41) | |||
| Skewness | 0.5192 | |||
| Kurtosis | 1.27 |
Neurosense Therapeutics Backtested Returns
Neurosense Therapeutics has Sharpe Ratio of -0.0458, which conveys that the firm had a -0.0458 % return per unit of risk over the last 3 months. Neurosense Therapeutics exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Neurosense Therapeutics' Mean Deviation of 4.63, risk adjusted performance of 0.014, and Downside Deviation of 5.33 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.31, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Neurosense Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Neurosense Therapeutics is expected to be smaller as well. At this point, Neurosense Therapeutics has a negative expected return of -0.27%. Please make sure to verify Neurosense Therapeutics' downside variance, as well as the relationship between the accumulation distribution and price action indicator , to decide if Neurosense Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.23 |
Weak predictability
Neurosense Therapeutics has weak predictability. Overlapping area represents the amount of predictability between Neurosense Therapeutics time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neurosense Therapeutics price movement. The serial correlation of 0.23 indicates that over 23.0% of current Neurosense Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.23 | |
| Spearman Rank Test | -0.29 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Pair Trading with Neurosense Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Neurosense Stock
| 0.62 | VERA | Vera Therapeutics | PairCorr |
| 0.59 | EQ | Equillium | PairCorr |
| 0.47 | DXB | Dimerix Earnings Call This Week | PairCorr |
| 0.44 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.35 | CDIOW | Cardio Diagnostics | PairCorr |
The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.
The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Neurosense Therapeutics Correlation, Neurosense Therapeutics Volatility and Neurosense Therapeutics Performance module to complement your research on Neurosense Therapeutics. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Neurosense Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.